Extended-release trazodone in major depressive disorder: A randomized, double-blind, placebo-controlled study

Psychiatry

Volumn 6, Issue 5, 2009, Pages 20-33

  Sheehan, David V ^a   Croft, Harry A ^b   Gossen, E Roderich ^c   Levitt, Randy J ^c   Brullé, Claire ^c   Bouchard, Sylvie ^d   Rozova, Anna ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b San Antonio Center for Clinical Research   (United States)

^c Labopharm Inc   (Canada)

^d Lakeshore General Hospital   (Canada)

Author keywords

Antidepressant; Extended release; Hamilton depression rating scale; Major depressive disorder; Placebo controlled trial; Serotonin 2 antagonist reuptake inhibitor (SARI); Trazodone

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; ANXIOLYTIC AGENT; CONTRAMID; HYPNOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; SEDATIVE AGENT; TRAZODONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CLINICIAN AND PATIENT GLOBAL IMPROVEMENT SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EJACULATION DISORDER; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPTIMAL DRUG DOSE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP PARAMETERS; SLEEP QUALITY; SOMNOLENCE; VITAL SIGN; XEROSTOMIA;

EID: 68349133563     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Nierenberg AA, Ostacher MJ, Huffman JC, et al. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med. 2008;50:428-436.
2. Saletu-Zyhlarz GM, Anderer P, Arnold O, et al. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiol. 2003;48:194-208.
3. Stahl SM. Antidepressants. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Third Edition. New York, NY: Cambridge University Press, 2008.
4. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4:33-355.
5. Falk WE, Rosenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psych Neurol. 1989;2:208-214.
6. Beasley CM, Jr., Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psych. 1991;52:294-299.
7. Kasper S, Olivieri L, Di LG, et al. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2005;21:1139-1146.
8. Munizza C, Olivieri L, Di LG, et al. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006;22:1703-1713.
9. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149:734-750.
10. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14:99-106.
11. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14:170-179.
12. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005;20:533-559.
13. Owens MJ, Morgan NW, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305-1322.
14. Krystal AD. Psychiatric comorbidity: the case for treating insomnia. Sleep Med Clin. 2006;1:359-365.
15. Farabaugh A, Mischoulon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005;20:87-91.
16. Fabre LF. Trazodone dosing regimen: experience with single daily administration. J Clin Psychiatry. 1990;51:23-26.
17. Desyrel® (trazodone HCl) product information sheet. New York, NY: Bristol-Myers Squibb Company, 2005.
18. Lenaerts V, Moussa I, Dumoulin Y, et al. Cross-linked high amylose starch for controlled release of drugs: recent advances. J Control Release. 1998;53:225-234.
19. Feighner JP. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psych. 1980;41:250-255.
20. Rickels K, Case WG. Trazodone in depressed outpatients. Am J Psych. 1982;139:803-806.
21. Perry PJ, Garvey MJ, Kelly MW, et al. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psych. 1989;50:290-294.
22. Mallinckrodt CH, Kaiser CJ, Watkin JG, et al. Type I error rates from likelihood-based repeated measures analyses of incomplete longitudinal data. Pharm Stat. 2004;3:171-186.
23. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64:413-420.
24. Brogden RN, Heel RC, Speight TM, et al. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs. 1981;21:401-429.
25. Brooks D, Prothero W, Bouras N, et al. Trazodone - a comparison of single night-time and divided daily dosage regimens. Psychopharmacol (Berl). 1984;84:1-4.
26. Debus JR, Rush AJ, Himmel C, et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry. 1988;49:422-426.
27. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60:28-31.
28. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59:1052-1060.
29. Goldberg HL, Finnerty RJ. Trazodone in the treatment of neurotic depression. J Clin Psychiatry. 1980;41:430-434.
30. Patten SB. The comparative efficacy of trazodone and imipramine in the treatment of depression. CMAJ. 1992;146:1177-1182.
31. Ashton AK, Jamerson BD, Weinstein WL, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2008;66:96-106.
32. Clayton AH, Favit A. Concerns in depression treatment: sexual dysfunction and weight gain. Prim Psychiatry. 2007;14:66-75.
33. Mann JJ. The medical management of depression. N Engl J Med. 2005;353:1819-1834.
34. Nurnberg HG. An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today (Barc). 2008;44:147-168.
35. Clayton AH, Favit A. Concerns in depression treatment: sexual dysfunction and weight gain. Prim Psychiatry. 2007;14:66-75.
36. Warner MD, Peabody CA, Whiteford HA, et al. Trazodone and priapism. J Clin Psychiatry. 1987;48:244-245.
37. Gartrell N. Increased libido in women receiving trazodone. Am J Psychiatry. 1986;143:781-782.
38. Sullivan G. Increased libido in three men treated with trazodone. J Clin Psych. 1988;49:202-203.
39. Lance R, Albo M, Costabile RA, et al. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology. 1995;46:117-120.
40. Meinhardt W, Schmitz PI, Kropman RF, et al. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res. 1997;9:163-165.
41. Stryjer R, Spivak B, Strous RD, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2008 [ePub ahead of print].